Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy

IMPORTANCE: This ongoing study assesses long-term safety and durability of response in infants with spinal muscular atrophy (SMA) type 1 after dosing with onasemnogene abeparvovec gene replacement therapy. OBJECTIVE: The primary objective of this ongoing study is to assess safety. The secondary obje...

Descripción completa

Detalles Bibliográficos
Autores principales: Mendell, Jerry R., Al-Zaidy, Samiah A., Lehman, Kelly J., McColly, Markus, Lowes, Linda P., Alfano, Lindsay N., Reash, Natalie F., Iammarino, Megan A., Church, Kathleen R., Kleyn, Aaron, Meriggioli, Matthew N., Shell, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129901/
https://www.ncbi.nlm.nih.gov/pubmed/33999158
http://dx.doi.org/10.1001/jamaneurol.2021.1272

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129901/
https://www.ncbi.nlm.nih.gov/pubmed/33999158
http://dx.doi.org/10.1001/jamaneurol.2021.1272

Ejemplares similares